Abstract
Despite product monograph warnings of post-retinoid sexual dysfunction (PRSD) for isotretinoin and recent policy decisions regarding the safety of isotretinoin, this study demonstrates that there remains conflicting and low-quality evidence on this topic and it is not possible to ascertain causation between retinoids and PRSD. Dermatologists and patients should be aware of the conflicting data regarding sexual dysfunction associated with systemic retinoid therapy. Routine screening for sexual side-effects during systemic retinoid treatment may be reasonable, as patients are less likely to self-disclose sexual health concerns.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have